Stay updated on Vyvanse Adolescent Safety Clinical Trial
Sign up to get notified when there's something new on the Vyvanse Adolescent Safety Clinical Trial page.

Latest updates to the Vyvanse Adolescent Safety Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe record describes a completed Phase 3 extension study evaluating long-term safety and efficacy of lisdexamfetamine (Vyvanse) in adolescents with ADHD, including eligibility criteria, 45 study locations, and outcome measures. It also provides the study’s results-related publication and record history.SummaryDifference60%

- Check17 days agoChange DetectedThe footer revision label changed from v3.7.2 to v3.8.0, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check24 days agoChange DetectedA banner announces updates to NIH websites and says the agency is using “Super Intelligence” in place of “Artificial Intelligence” during the transition.SummaryDifference1%

- Check31 days agoChange DetectedThe footer revision marker changes from v3.7.1 to v3.7.2 on the ClinicalTrials.gov error page.SummaryDifference0.2%

- Check38 days agoChange DetectedThe footer revision label changes from v3.7.0 to v3.7.1 while the page continues to show a 403 Forbidden error.SummaryDifference0.2%

- Check59 days agoChange DetectedThe study page now displays a 403 error, replacing the previous content with an access-restricted page and preventing users from viewing the study details and related information.SummaryDifference17%

Stay in the know with updates to Vyvanse Adolescent Safety Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Vyvanse Adolescent Safety Clinical Trial page.